Potent PARG inhibitors (PARGis) have been developed (PDD00017273 and JA2131) (32,33) that show promise when combined with irradiation (34) but are minimally effective (against ovarian cancer cells) as a single agent unless targeted to cancers with replication defects or combined with CHK1 inhibitors (35). Here, PARG is linked to cancer.